CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Activities
Net income (loss)	$ 109,625	$ (1,281)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	33,396	29,077
Amortization of debt issuance costs and Royalty Rights	304	194
Gain on extinguishment of debt	(1,046)	0
Recurring fair value measurements of assets and liabilities	18,939	3,914
Stock-based compensation	7,504	3,545
Provisions for inventory and other assets	3,265	1,368
Deferred income taxes	(80,375)	0
Changes in assets and liabilities, net of acquisition:
Accounts receivable	(996)	(11)
Inventories	(6,593)	4,268
Prepaid and other assets	8,019	3,600
Accounts payable and other accrued liabilities	(10,208)	(28,699)
Accrued rebates, returns and discounts	(3,236)	(10,452)
Net cash provided by operating activities	78,598	5,523
Investing Activities
Purchases of property and equipment	(274)	(53)
Net cash used in investing activities	(42,673)	(18,525)
Financing Activities
Proceeds from issuance of 2027 Convertible Notes	70,000	0
Payment in connection with 2024 Senior Notes	(70,750)	(9,500)
Payment of debt issuance costs	(4,084)	0
Payment of contingent consideration	(7,845)	(4,807)
Payment of Royalty Rights	(1,297)	(968)
Proceeds from issuance of common stock	7,020	44,861
Proceeds from exercise of stock options	34	193
Shares withheld for payment of employee's withholding tax liability	(872)	(418)
Net cash (used in) provided by financing activities	(7,794)	29,026
Net increase in cash and cash equivalents	28,131	16,024
Cash and cash equivalents at beginning of year	36,810	20,786
Cash and cash equivalents at end of year	64,941	36,810
Supplemental Disclosure of Cash Flow Information
Net cash received for refund of income taxes	6,913	0
Cash paid for interest	7,752	10,124
Supplemental Disclosure of Non-Cash Investing Activities
Deferred payments for acquisition of Otrexup intangible assets	0	26,021
Otrexup
Investing Activities
Purchase of Otrexup	(27,027)	(18,472)
Acquestive Therapeutics, Inc
Investing Activities
Purchase of Otrexup	(15,372)	0
Convertible Senior Notes, 2.5% | Convertible debt
Financing Activities
Payments in connection with convertible notes	$ 0	$ (335)